Categories Analysis, Technology

Infosys earnings preview: Wall St expects higher revenues on flat EPS in Q1

Information technology firm Infosys (NYSE: INFY) is slated to report first-quarter 2020 earnings results before the market opens on Friday, July 12. Wall Street expects the Indian firm’s profits to be flat at 13 cents per share, even as revenues are projected to improve 8.7% year-over-year to $3.08 billion.

Infosys Canary Wharf building in UK
Image Courtesy: Infosys

Wage hikes in the first quarter, as well as higher costs related to H1-B visa fees, are likely to have contributed to squeezed margins, restricting the flow of revenues down the line.

In the last-reported quarter, the company reported a 2% increase in earnings, helped by higher revenues as well as lower income tax expenses. Net profit rose 2% to $581 million, while revenues grew by 9.1% to $3.06 billion.   

READ: Samsung forecasts a 56% drop in Q2 earnings

Infosys also predicted fiscal 2020 revenue growth in the range of 7.5% to 9.5% in constant currency and operating margin in the range of 21% to 23%. The management had vowed to deploy certain steps to improve operational efficiencies, about which they are likely to brief during the earnings conference call.

Infosys shares have mostly traded sidewise in the past 12 months. Since the start of this year, the stock has gained 10%.

Infosys (NYSE: INFY) reported a 2% increase in earnings for the fourth quarter of 2019.

Peer firms Wipro Limited (NYSE: WIT) and International Business Machines (NYSE: IBM) are scheduled to post quarterly results on July 16. Late last month, meanwhile, Accenture (NYSE: ACN) reported a 4% increase in revenues in the third quarter of 2019 to $11.1 billion, surpassing the Wall Street projection of $11.04 billion.  

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top